Abiopharma

Quarterly report 1 for 2026

argenx to Host Myositis R&D Webinar on June 23, 2026

Communiqué de presse : Le venglustat de Sanofi a été accepté pour un examen prioritaire aux États-Unis afin de traiter la maladie de Gaucher de type 3

Press Release: Sanofi’s venglustat accepted for priority review in the US to treat type 3 Gaucher disease

Dormant shares - change in the number of shares

The company’s liability position as of 31.3.26, by maturity dates

Quarterly report 1 for the year 2026

Dividend in the amount of 130.5646 agorot per share, ex-dividend date 4.6.26, payment 22.6.26

Events and transactions

Change in holdings of interested parties/officers - Linda Ben Shoshan